The FDA Criticised for not Enforcing The Synthetic Nicotine Ban

Industry InsightRegulations
Jul.18.2022
After being criticised for not enforcing the synthetic nicotine ban, the FDA started sending warnings to non-authorized manufacturers and retailers of the products.

On July 13th the FDA announced that it sent two warning letters to manufacturers marketing non-authorized synthetic nicotine products and over 100 warning letters to retailers selling synthetic nicotine products to minors.

The FDA Criticised for not Enforcing The Synthetic Nicotine Ban

 

Synthetic products, which are often sold in fruity flavors and are popular with teens, have previously been exempt from FDA regulations because they are made from nicotine made in a lab, rather than nicotine extracted from tobacco leaf.

However, following a legislation enacted on March 15th, the US Food and Drug Administration (FDA) has been given the authority to regulate tobacco products containing nicotine from any source. This has led to a ban on synthetic nicotine.

 

After the passing of the synthetic nicotine ban, the Vapor Trade Association (VTA) immediately began working on a strategy to ensure a viable path for companies which are selling the products. Moreover, the VTA’s Board of Directors and members met with the FDA Center for Tobacco Products (CTP) to discuss the ban.

 

The FDA personnel in attendance included over 35 senior leaders, representing seven different offices inside CTP. The VTA held presentations by three Ph.D’s in Organic Chemistry and Physical Analytical Chemistry, in order to frame critical scientific and public policy issues that we believe had not previously been presented to or considered by the FDA.

 

Synthetic nicotine manufacturers had to submit premarket applications by May 14th

 

The March legislation required synthetic nicotine manufacturers to submit premarket applications by May 14, 2022, and any brand which had not submitted these documents would be considered illegal. However, until earlier this week this had never been enforced by the FDA.

 

Naturally this led to the agency being heavily criticised. In a letter, which cited STAT’s reporting on the agency’s lack of action, Senators Dick Durbin (D-Ill.) and Susan Collins (R-Maine), said that the FDA “appears to be on the brink of failing yet again at protecting our nation’s children.”

 

Meanwhile, on July 13th the FDA announced that it sent two warning letters to manufacturers marketing non-authorized synthetic nicotine products and over 100 warning letters to retailers who sold synthetic nicotine products to minors.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

 

 

Kansas Lawmakers Hear SB 355 to License E-Cigarette Makers, Citing Illicit China Imports
Kansas Lawmakers Hear SB 355 to License E-Cigarette Makers, Citing Illicit China Imports
Kansas lawmakers held a Senate committee hearing on Senate Bill 355 on Jan. 27. The proposal would require e-cigarette manufacturers—potentially affecting distributors as well—to obtain a state license, expanding oversight beyond retailers.
Jan.28 by 2FIRSTS.ai
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
According to KT&G’s official website (Feb 5, 2026), KT&G released its 2025 fourth-quarter and full-year results. Driven by strong growth in its overseas cigarette business and a rebound in its real estate business, the company posted double-digit increases in both revenue and operating profit, reaching record-high performance.
Feb.05 by 2FIRSTS.ai
Kardinal to Launch Dual Open-System Devices Globally in Q1 2026
Kardinal to Launch Dual Open-System Devices Globally in Q1 2026
Kardinal OS and Syn Signal Strategic Expansion in Open-System ENDS
Dec.31
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
KT&G’s Heated Tobacco Brand “lil” Named to Korea’s Brand Hall of Fame for Eighth Consecutive Year
KT&G’s Heated Tobacco Brand “lil” Named to Korea’s Brand Hall of Fame for Eighth Consecutive Year
KT&G said its heated tobacco brand “lil” was selected as an outstanding brand in the heated tobacco category of the “2026 Korea Brand Hall of Fame,” marking its eighth straight year on the list. The awards are organized by the Industrial Policy Research Institute (IPS) and determined through a composite evaluation of customer satisfaction, brand value and market performance.
Jan.26 by 2FIRSTS.ai